INTRODUCTION {#s1}
============

Young women, traditionally defined as age ≤ 40 years at diagnosis,^[@B1]^ account for 4% of women with breast cancer in the United States^[@B2]^ and are more likely than older women to be diagnosed at later stages and with more aggressive subtypes, including poorly differentiated, estrogen receptor (ER)-negative, and human epidermal growth factor receptor 2--positive (HER2+) disease.^[@B3]-[@B7]^ Young age has also been considered an independent risk factor for recurrence, particularly with ER-positive (ER+) disease.^[@B5]-[@B10]^ In multiple studies, over 85% of young women with breast cancer have received adjuvant chemotherapy.^[@B3],[@B11],[@B12]^ Yet, the majority of breast cancers diagnosed in young women are ER+/HER2-negative (HER2−),^[@B9]^ a subgroup with lesser chemotherapy benefit than the HER2+ and triple-negative subgroups.^[@B13]^

Correspondingly, efforts have been made in recent years to improve risk stratification in ER+/HER2− disease, particularly with gene expression profiles (GEP), with the aim of reserving chemotherapy for those likely to benefit and sparing those who are not. The 21-gene recurrence score (RS; Onco*type* Dx; Genomic Health, Redwood City, CA) assay was initially evaluated among axillary lymph node--negative (N0) patients and later for postmenopausal women with node-positive breast cancer.^[@B14]-[@B18]^ Recently, results of the phase III Trial Assigning Individualized Options for Treatment (TAILORx; ClinicalTrials.gov identifier: [NCT00310180](https://ClinicalTrials.gov/ct2/show/NCT00310180)) demonstrated very low distant recurrence risk (DRR) among women with N0 breast cancer and RS 0-10, and no benefit from chemotherapy among women with RS 11-25, with a suggestion of benefit among women ≤ 50 years of age with RS 16-25 in a subset analysis.^[@B19],[@B20]^ In contrast, DRR was higher among women with RS ≥ 26.^[@B20]^ In previous studies, chemotherapy reduced 10-year DRR among women with RS ≥ 31 by 28%, although only 14% of patients undergoing RS testing have RS ≥ 31.^[@B15],[@B21]^ These and other data have led to the widespread use of the RS assay and an associated decline in chemotherapy use for ER+/HER2− breast cancer.^[@B22],[@B23]^

However, concerns about avoiding chemotherapy have arisen for young women with ER+/HER2− breast cancer, given their higher risk of recurrence, and use of the RS assay has not been adopted to the same extent as in older women.^[@B22]^ The small proportion (5%-10%) of women \< 40 years of age in validation studies contributes to this apprehension.^[@B14]-[@B17],[@B19]^ In an effort to address this gap, we sought to evaluate the prognostic impact of the RS assay in young women with stage I-III ER+/HER2− breast cancer unselected for RS testing enrolled in a prospective cohort study.

METHODS {#s2}
=======

Study Design {#s3}
------------

The Young Women's Breast Cancer Study is a multicenter, prospective cohort of women diagnosed with breast cancer at ≤ 40 years of age, enrolled between 2006 and 2016 from 13 sites in the United States and Canada. Women with newly diagnosed breast cancer (\< 6 months from diagnosis to enrollment) and able to respond to questionnaires in English were eligible. Potential participants at the Dana-Farber/Harvard Cancer Center (DF/HCC) sites were identified by the Rapid Case Identification Core through pathology review and at other sites through systematic review of clinic lists. Participants provided written informed consent. Institutional review board approval was obtained through DF/HCC and other participating centers.

Patient, disease, and treatment information was obtained through medical record review. ER and progesterone receptor positivity were defined as immunohistochemistry ≥ 1% and HER2 status using American Society of Clinical Oncology (ASCO) guidelines in use at diagnosis. Amenorrhea was evaluated by patient report on surveys completed at baseline, every 6 months for 3 years, then annually, and defined as absence of menses in the 6 months prior to the survey completed 1 year following diagnosis, to reflect that chemotherapy-related amenorrhea (CRA) has commonly been evaluated at the 1 year time point but that menses may continue beyond initiation of treatment.^[@B24]^ If data were unavailable at 1 year, amenorrhea was defined as absence of menses in the 12 months before the 18-month survey.

Selection for RS testing and RS results were abstracted from medical records when records indicated that testing was performed. For those who did not undergo RS testing as part of clinical care, RS testing was performed by Genomic Health (Redwood City, CA) on banked tissue obtained before initiation of systemic therapy. Recurrences reported by patients on surveys were confirmed (or refuted) through medical record review and characterized as distant recurrence versus other (ie, local/regional). Date of death was obtained through medical record review, obituaries, and family report. Analysis of selection for RS testing included all women with stage I-III breast cancer. Analyses of distant recurrence-free survival (DRFS) were limited to women with N0 or N1 (1-3 positive nodes, including micrometastases) breast cancer and an available RS result.

Statistical Analysis {#s4}
--------------------

The χ^2^ test was used to compare chemotherapy use by nodal status and receipt of RS testing during clinical care. Logistic regression models were used to assess factors associated with RS testing during clinical care. DRFS (primary outcome) was defined as the interval from diagnosis to distant recurrence or (if the latter was unknown), breast cancer--specific death. Patients were censored at last follow-up. DRFS was assessed using Kaplan-Meier survival estimates through 6 years, the median follow-up when this analysis was performed. DRFS was analyzed both by TAILORx risk groups (\< 11, 11-25, and ≥ 26) and traditional risk groups (RS \< 18, 18-30, ≥ 31) to reflect that TAILORx risk groups have been widely adopted in clinical practice since spring 2018, when these data became public, but traditional risk groups were used while patients in this study made chemotherapy decisions and to evaluate whether the different groups better stratified risk in N0 versus N1 breast cancer. A 2-degrees-of-freedom log-rank test was used to compare outcomes across RS groups. Multivariable Cox proportional hazards models were used to assess factors associated with DRFS. Factors significant at a level of *P* \< .20 in univariable analysis were tested in the multivariable model.^[@B25]^ Outcomes by receipt of chemotherapy were evaluated in the RS 11-25 group using Kaplan-Meier survival as an exploratory analysis because administration of chemotherapy was not randomly assigned. All analyses were performed using SAS, Version 9.4 (SAS Institute, Cary, NC). All statistical tests were 2-sided, with a .05 level of significance.

RESULTS {#s5}
=======

Disease and Treatment Information {#s6}
---------------------------------

Of 577 eligible women with stage I-III ER+/HER2− breast cancer, 509 had an RS performed during clinical care (n = 189) or on banked tissue (n = 320; [Fig 1](#f1){ref-type="fig"}). Disease, demographic, and treatment data are presented in [Table 1](#T1){ref-type="table"}. Median age at diagnosis was 37.2 years (17.7-40.9 years). Most women (n = 300; 58.9%) had N0 disease; 163 women (32.0%) had N1 disease. Three hundred fifty-five (69.7%) received chemotherapy, although use varied by nodal status (N0 disease, 53.0% *v* N1 disease, 92.6%; *P* \< .0001). Fifty-seven patients (11.2%) received ovarian suppression, either with a gonadotropin-releasing hormone agonist or bilateral oophorectomy. Of 417 evaluable women, including the 57 who received ovarian suppression, 192 (46.0%) reported amenorrhea. RS ranged from 3-77. Among N0 patients (n = 300), 11.0% had RS \< 11, 65.0% had RS 11-25, and 24.0% had RS ≥ 26, among whom 21.2%, 44.1%, and 91.7% received chemotherapy, respectively.

![Study flow diagram. DRFS, distant recurrence-free survival; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; RS, recurrence score; TisN+, in situ disease in breast, axillary node-positive.](JCO.19.01959f1){#f1}

###### 

Patient, Disease, and Treatment Characteristics
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Selection for RS Testing During Clinical Care {#s7}
---------------------------------------------

Selection for RS testing during clinical care among women with stage I-III ER+/HER2− breast cancer varied by disease and demographic features ([Table 2](#T2){ref-type="table"}). In multivariable analysis, women who were younger (OR~age~ [~\<~]{.ul} ~30~ *~v~* ~36-40\ years~ = 0.46; 95% CI, 0.24 to 0.88), had larger tumors (OR~T2-4~ *~v~* ~T1~ = 0.61; 95% CI, 0.39 to 0.95), or had node-positive disease (OR~N1~ *~v~* ~N0~ = 0.16, 95% CI, 0.10 to 0.27; OR~N2/3~ *~v~* ~N0~ = 0.02, 95% CI, 0.003 to 0.15) were less likely to have an RS, and patients with grade II tumors were more likely to have an RS (OR~grade\ II~ *~v~* ~III~ = 3.23; 95% CI, 2.00 to 5.20). Among the 189 women who had an RS assay during clinical care, 164 (86.8%) were N0, 24 (12.7%) were N1, and 1 (0.5%) had ≥ 4 positive nodes. RS distributions appeared to vary by selection for RS testing (Appendix [Table A1](#TA.1){ref-type="table"}, online only). Patients who had an RS performed during clinical care were less likely to receive chemotherapy for N0 (65/164 \[39.6%\] *v* 94/135 \[69.1%\]; *P* \< .0001) and N1 disease (18/24 \[75.0%\] *v* 133/139 \[95.7%\]; *P* = .0003).

###### 

Characteristics Associated With RS Testing During Clinical Care
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Disease Outcomes by RS Risk Groups {#s8}
----------------------------------

Median follow-up for the 509 women with an RS was 6.0 years (range, 0-11.4 years). All DRFS events (n = 55) were distant recurrence, and no breast cancer deaths without distant recurrence occurred. Among women with N0 disease, 6-year DRFS rates were 94.4% (RS, \< 11), 96.9% (RS, 11-25), and 85.1% (RS, ≥ 26; [Fig 2](#f2){ref-type="fig"}). Among women with N1 disease, 6-year DRFS rates were 92.3% (RS \< 11), 85.2% (RS, 11-25), and 71.3% (RS, ≥ 26). In univariable analysis, features associated with 6-year DRR were tumor stage, node status, grade, chemotherapy use, and RS. Young age (≤ 30 or 31-35 *v* 36-40 years) and amenorrhea were not associated with 6-year DRR. In the multivariable model, tumor size (hazard ratio \[HR\]~T1~ *~v~* ~T2-4~ = 0.45; 95% CI, 0.26 to 0.80), node status (HR~N1~ *~v~* ~N0~ = 2.23; 95% CI, 1.29 to 3.85), and RS (HR[~\<~]{.ul} ~25~ *~v~* ~\>\ 25~ = 0.48; 95% CI, 0.27 to 0.85) remained associated with 6-year DRR, whereas grade (HR~II~ *~v~* ~I~ = 2.58, 95% CI, 0.61 to 10.97; HR~III~ *~v~* ~I~ = 2.92, 95% CI, 0.67 to 12.83) and chemotherapy (HR~yes~ *~v~* ~no~ = 0.74, 95% CI, 0.33 to 1.64) did not ([Table 3](#T3){ref-type="table"}).

![Distant recurrence-free survival (DRFS) by (A and B) traditional and (C and D) TAILORx recurrence score (RS) risk groups.](JCO.19.01959f2){#f2}
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Characteristics Associated With 6-Year Distant Recurrence Risk Among Women With N0 or N1 Disease

![](JCO.19.01959t3)

DRFS varied significantly using TAILORx cutoffs for those with N0 (log-rank *P* \< .001) but not N1 disease (log-rank *P* = .10; [Fig 2](#f2){ref-type="fig"}). DRFS varied significantly using traditional cutoffs both in N0 (log-rank *P* = .006) and N1 disease (log-rank *P* = .004).

Among women with N0 disease and RS 11-25 (n = 195), 86 (44.1%) received chemotherapy and 109 (55.9%) did not. Two women (2.3%) who received chemotherapy and 6 (5.5%) who did not experienced a distant recurrence. In an exploratory analysis, chemotherapy use was not associated with DRFS (log-rank *P* = .25) in this subgroup ([Fig 3](#f3){ref-type="fig"}).

![Distant recurrence-free survival (DRFS) by chemotherapy (chemo) use in women with N0 breast cancer and recurrence score 11-25.](JCO.19.01959f3){#f3}

DISCUSSION {#s9}
==========

Consensus guidelines specific to young women with breast cancer support use of GEP to assist in chemotherapy decision making, but comment that only a small minority of women in validation studies were ≤ 40 years of age at diagnosis.^[@B26]^ This population has experienced inferior disease outcomes, including survival, relative to women age 40-49 years.^[@B6],[@B27]^ For this reason and others, adoption of GEP in the care of young women with ER+/HER− breast cancer has lagged behind older women, and data regarding GEP specifically in women age \< 40 years, rather than grouping all women age \< 50 years, are needed to inform chemotherapy decision making. Recently, TAILORx demonstrated that the RS is prognostic of outcomes and predictive of chemotherapy benefit among women age ≤ 50 years, but raised questions about how to incorporate assay results into chemotherapy decision making.^[@B20]^ Correspondingly, the ASCO Clinical Practice Guideline was updated to incorporate the TAILORx data and supports chemoendocrine therapy or endocrine therapy for women age ≤ 50 years with RS 16-25.^[@B28]^ However, only 5% of women with RS 11-25 in TAILORx were ≤ 40 years of age (n = 203), and the analysis did not adjust for CRA. Our study demonstrates that, in a large prospective cohort of women ≤ 40 years of age at diagnosis, RS is independently prognostic of DRR among women with N0 and N1 disease, further supporting that both traditional and genomic risk factors are important in selecting treatment of women ≤ 40 years of age.

Although young age has not been an independent risk factor in studies associating RS with outcomes,^[@B14]^ concerns have remained that host or tumor differences that impart independent risk to young women with ER+/HER2− breast cancer could alter the performance of GEP. Supported by data demonstrating greater chemotherapy benefit,^[@B13]^ some have suggested that the threshold for chemotherapy in young women might be lower to address risk due to young age. Furthermore, an unplanned, post hoc subset analysis of TAILORx found that chemotherapy was associated with a reduction in DRR among women \< 50 years of age with RS 21-25 and, to a lesser extent, RS 16-20.^[@B20]^ Many have wondered whether the observed chemotherapy benefit could be attributable at least in part to CRA,^[@B29]^ particularly because ovarian function suppression (OFS) was used in a small minority and because the benefit became evident only after 5 years postdiagnosis. In our study, amenorrhea 1 year after diagnosis was not associated with DRR, raising the question of whether amenorrhea at a later time point may be a more valuable biomarker, given that many women ≤ 40 years of age later resume menstrual function.^[@B30]^ A subsequent analysis of TAILORx found that chemotherapy benefit among women ≤ 50 years of age with RS 11-25 was limited to premenopausal women 46-50 years of age, supporting the hypothesis that chemotherapy benefit may have been derived through CRA, given that women older than premenopausal women are significantly more likely to undergo CRA than younger women.^[@B31]^

Our data show that DRFS was high for women with N0 disease and RS \< 11 or RS \< 18, among whom only a minority received chemotherapy. Importantly, our population includes those for whom the RS was not performed during clinical care, a group enriched for higher-risk clinical features. Low DRR through 6 years further demonstrates that young women with RS \< 11 and RS 11-15 have little risk within the first 5 years to improve on, supporting the application of TAILORx findings regarding lack of chemotherapy benefit for women ≤ 50 years of age with RS \< 11 and RS 11-15 to women ≤ 40 years of age. In this cohort, 10% of node-negative patients who did not have an RS assay performed during clinical care were found to have an RS \< 11, suggesting that broader RS assay use among young patients may reduce chemotherapy use without compromising outcomes.

Whether there is benefit from chemotherapy for patients ≤ 40 years of age with RS 16-20 or 21-25 is not directly addressed by our analysis. We observed no difference in DRFS in the intermediate risk group (RS 11-25) by receipt of chemotherapy, and the event rate was low in both subgroups, suggesting that there may be no or limited benefit. The recent TAILORx analysis showing no chemotherapy benefit among women ≤ 50 years of age with RS 16-20 and low clinical risk raises additional questions about the benefit of chemotherapy in this setting.^[@B31]^

On the other end of the spectrum, our data demonstrate that young women with node-negative disease and RS ≥ 26 or RS ≥ 31, the majority of whom had T1 tumors, experience moderate rates of early distant recurrence despite high rates of chemotherapy use. Most striking is the relatively poor 6-year DRFS among those with N1 disease and high risk scores despite near universal chemotherapy use, underscoring the need for improved therapies. The vast majority of patients in this study did not receive OFS, which substantially improved distant recurrence rates and survival in the Suppression of Ovarian Function (SOFT; ClinicalTrials.gov identifier: [NCT00066690](https://ClinicalTrials.gov/ct2/show/NCT00066690)) and Tamoxifen and Exemstane Trial (TEXT; ClinicalTrials.gov identifier: [NCT00066703](https://ClinicalTrials.gov/ct2/show/NCT00066703)) trials, with particularly large benefits for women \< 35 years of age, highlighting the importance of considering OFS use for those with higher-risk disease.^[@B32]-[@B35]^

Whether and to what degree young women with node-positive disease but low or low-intermediate RS benefit from chemotherapy remain unanswered questions. In 2010, Albain et al^[@B17]^ published the first validation study evaluating the RS assay in node-positive breast cancer. The analysis was limited to postmenopausal women, and data evaluating whether RS is predictive of chemotherapy benefit for node-positive premenopausal women remain limited. The Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT; ClinicalTrials.gov identifier: [NCT00433589](https://ClinicalTrials.gov/ct2/show/NCT00433589)) trial randomly assigned 1,550 women with high clinical and low genomic risk using the MammaPrint assay (Agendia, Irvine, CA), 48% of whom had N1 disease, to endocrine therapy with or without chemotherapy and showed no difference in 5-year DRFS (95.9 *v* 94.9%; *P* = .27), with no difference in outcomes by age, although fewer than 10% were \< 40 years of age.^[@B36],[@B37]^ The West German Study Group Plan B trial (ClinicalTrials.gov identifier: [NCT01049425](https://ClinicalTrials.gov/ct2/show/NCT01049425)) included 348 women with RS ≤ 11 treated with endocrine therapy alone (median age of 56 years; 31% with N1 disease), among whom 5-year DRFS was 98% in both N0 and N1 patients.^[@B38],[@B39]^ The most recent TAILORx analysis also found no association between clinical risk, albeit in the node-negative setting, and distant recurrence among women ≤ 50 years of age with RS 0-10.^[@B31]^ These studies provide reasonably strong data suggesting that endocrine therapy alone may be appropriate for select premenopausal women with N1 disease and low GEP risk. Premenopausal women are included in RxPONDER (ClinicalTrials.gov identifier: [NCT 01272037](https://ClinicalTrials.gov/ct2/show/NCT01272037)), in which patients with node-positive ER+/HER2− breast cancer with RS 0-25 are randomly assigned to endocrine therapy with or without chemotherapy, but will represent a minority, particularly those ≤ 40 years of age. In our study, although the majority of women with N1 disease and RS \< 11 had received chemotherapy, their fairly good outcomes, coupled with prior data showing no benefit from adjuvant chemotherapy in N1 patients with low-risk GEP, suggest that GEP are likely to be valuable tools in chemotherapy decision making for premenopausal women with N1 breast cancer in the future. In addition, RS cutpoints (traditional *v* TAILORx) may stratify disease outcomes differently in N0 versus N1 breast cancer. Given the increased anatomic risk, it is conceivable that lower-risk cutoffs will better differentiate risk among node-positive patients, although our data do not clearly demonstrate this. Additional data (eg, RxPONDER) regarding an optimal clinical cutpoint in node-positive breast cancer are awaited, and we encourage additional analyses from other datasets of young women, even in which chemotherapy was not randomly assigned, such as SOFT/TEXT and the Austrian Breast and Colorectal Cancer Study Group trial 12, to further explore GEP in premenopausal women.

Our findings should be interpreted in light of their limitations. First, we are not at this time able to address risk of later recurrences because our median follow-up was 6 years. Future analyses evaluating longer-term disease outcomes in this cohort are planned, although chemotherapy benefit, which has generally been limited to the first 5 years after diagnosis, seems unlikely to be affected substantially. Second, we were unable to formally evaluate whether RS is predictive of chemotherapy benefit because receipt of chemotherapy was not randomly assigned in this prospective observational cohort. An exploratory analysis among those with N0 disease and RS 11-25 showed no difference in 6-year DRFS by receipt of chemotherapy. We attempted to perform an additional exploratory analysis in this subgroup using propensity score analysis, but were unable to develop a balanced model because of limitations on measured covariables associated with treatment decisions. Third, our ability to evaluate the association between CRA and DRR may have been limited by missing information and by resumption of menses after CRA evaluation on the 1-year survey.

In conclusion, in a cohort of young women unselected for RS testing during clinical care, RS is prognostic of DRR among those with N0 and N1 breast cancer and is a valuable tool for risk stratification. Future analyses should seek to determine whether GEP are predictive of chemotherapy benefit among young women, with the goal of optimizing breast cancer outcomes and minimizing short- and long-term toxicities.
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TABLE A1.RS Distributions by Selection for RS Testing
